BioStem (BSEM) CEO Jason Matuszewski Exercises 25,119 Options

What Happened
Jason Matuszewski, CEO of BioStem Technologies (BSEM), reported exercises/conversions of derivative securities (transaction code M) that resulted in the acquisition and immediate disposition of a total of 25,119 shares: 8,469 shares on 2026-09-15 and 16,650 shares on 2026-09-17. Each line shows an exercise price of $0.00 and $0 cash reported for the acquisitions and disposals (i.e., no purchase price or proceeds are shown in the filing).

Key Details

• Transaction dates: 2026-09-15 (8,469 shares) and 2026-09-17 (16,650 shares).
• Transaction type/code: M = exercise or conversion of derivative; each exercise was reported as both an acquisition and a disposal of the derivative.
• Price: $0.00 reported for the exercises (no cash paid or proceeds shown).
• Shares acquired/disposed: 25,119 total (8,469 + 16,650).
• Shares owned after transaction: Not specified in the information provided.
• Footnote of note: F1 indicates the options involved are fully vested and exercisable.
• Filing: Form 4 filed 2026-09-17 for the period ending 2026-09-15; filing appears timely based on the reported dates.
• Exhibit/remark: Exhibit 24 (Power of Attorney).

Context
The filing shows an exercise/conversion of derivative instruments followed by immediate disposition/settlement of the underlying shares. For retail investors, exercises can be routine (e.g., option vesting and conversion) and do not necessarily signal a change in insider sentiment. Because the report shows $0 exercise price and no proceeds, it may represent conversion/settlement mechanics rather than a cash purchase or a cash sale; the filing does not provide additional details about whether shares were sold in the open market, net-settled, or otherwise disposed.